Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DBH | P09172 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2284682 | 0.85 | ACHE (0.30) | ACHE | |
| SCHEMBL944353 | 0.85 | ACHE (0.34) | ACHEPDGFRBPDGFRATUBB1 | |
| SCHEMBL2285289 | 0.84 | CA2 (0.40) | — | |
| SCHEMBL2285403 | 0.84 | TAS1R3 (0.31) | KDM4EALDH1A1 | |
| SCHEMBL2286381 | 0.80 | TAAR1 (0.32) | — | |
| SCHEMBL15390519 | 0.80 | CYP11B1 (0.33) | KDM4EALDH1A1 | |
| SCHEMBL2287967 | 0.80 | AR (0.32) | — | |
| SCHEMBL3697378 | 0.77 | — | — | |
| SCHEMBL1567876 | 0.74 | — | — | |
| SCHEMBL29067299 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118221570-A | Triglocarbazole dual-function passivation material for perovskite solar cell and synthesis method and application thereof | 江苏大学 | 2024-06-21 | — | — | CN | claimed |
| CN-114621286-B | Fluoroalkyl-substituted trivalent organic phosphine compound, and preparation method and application thereof | 中山大学 | 2024-02-27 | — | — | CN | claimed |
| CN-114621286-A | Fluoroalkyl-substituted trivalent organic phosphine compound and preparation method and application thereof | 中山大学 | 2022-06-14 | — | — | CN | claimed |
| CN-108174603-B | 1-heteroaryl-indoline-4-carboxamides as GPR52 modulators | 阿芮纳制药有限公司 | 2021-07-02 | — | — | CN | claimed |
| EP-3292114-B1 | 1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2020-03-11 | — | — | EP | claimed |
| CN-107074822-B | Triazole compounds as T-type calcium channel blockers | 爱杜西亚药品有限公司 | 2020-01-03 | — | — | CN | claimed |
| CN-106414429-B | Pyrazole compounds and their use as T-type calcium channel blockers | 爱杜西亚药品有限公司 | 2020-01-03 | — | — | CN | claimed |
| US-10246426-B2 | Triazole compounds as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-04-02 | — | — | US | claimed |
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-09-04 | — | — | US | claimed |
| EP-3194374-B1 | TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-08-01 | — | — | EP | claimed |
| WO-2016041892-A1 | TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-03-24 | — | — | WO | claimed |
| WO-2015186056-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-10 | — | — | WO | claimed |
| US-9120744-B2 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-09-01 | — | — | US | claimed |
| EP-2493877-B1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-17 | — | — | EP | claimed |
| US-8513271-B2 | Pyrimidine compounds as delta opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-20 | — | — | US | claimed |
| EP-2493877-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2012-09-05 | — | — | EP | claimed |
| US-20110269759-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2011-11-03 | — | — | US | claimed |
| WO-2011053705-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | WO | claimed |
| US-20110105520-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2011-05-05 | — | — | US | claimed |
| US-20100137194-A1 | Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2010-06-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | CACNA1E, CACNA1I, CACNA1G | DBH 4250/4885KDM4E 3649/4885ALDH1A1 3435/4885 |
| US-20100137194-A1 | Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism | SERPINE1, PLAT, SERPINB1 | DBH 2507/4885KDM4E 3907/4885ALDH1A1 918/4885 |
| US-10246426-B2 | Triazole compounds as T-type calcium channel blockers | CACNA1I, CACNA1E, CACNA1G | DBH 4067/4885KDM4E 3001/4885ALDH1A1 3606/4885 |
| US-20110105520-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | OPRD1, OPRK1, OPRM1 | DBH 578/4885KDM4E 3770/4885ALDH1A1 238/4885 |
| US-20110269759-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | OPRD1, OPRK1, OPRM1 | DBH 446/4885KDM4E 3260/4885ALDH1A1 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.